- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04317781
Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant
Tagraxofusp (SL-401) Therapy for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patients Post-Autologous or Post-Allogeneic Hematopoietic Cell Transplantation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVE:
I. To evaluate the safety of tagraxofusp-erzs (tagraxofusp) in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) after autologous (auto) or allogeneic (allo) hematopoietic cell transplantation (HCT).
SECONDARY OBJECTIVES:
I. To estimate progression-free survival (PFS) in patients with BPDCN receiving maintenance therapy with tagraxofusp after auto-HCT or allo-HCT.
II. To estimate the overall survival (OS) in patients with BPDCN receiving maintenance therapy with tagraxofusp after auto-HCT or allo-HCT.
OUTLINE:
Within day 45 and 180 after stem cell transplant, patients receive tagraxofusp-erzs intravenously (IV) over 15 minutes on days 1-3 of cycles 1-4 and days 1-2 of subsequent cycles. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for up to 1 year.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- M D Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Eligible patients will be aged >= 18 years. Pediatric patients age 2 years and older will be considered on a case by case basis.
- Diagnosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN) according to World Health Organization (WHO) classification or confirmed by hematopathology
- The patients must be in partial response or better
- > 30 days post-transplant without active or chronic infections
- Karnofsky performance status >= 60%; Lansky >= 60
- Left ventricular ejection fraction (LVEF) >= institutional lower limit of normal by multigated acquisition (MUGA) scan or echocardiogram within 30 days of first protocol treatment
- Diffusion capacity of the lung for carbon monoxide (DLCO) > 40% of predicted value (corrected for hemoglobin) within 3 months of registration
- Forced expiratory volume in 1 second (FEV1) > 40% of predicted value within 3 months of registration
- Forced vital capacity (FVC) > 40% of predicted value within 3 months of registration
- Serum creatinine =< 1.5 mg/dL (133 mmol/L)
- Serum albumin >= 3.2 g/dL (or >= 32 g/L) without IV albumin within the previous 72 hours
- Bilirubin =< 1.5 x the upper limit of normal ([ULN] except patients with Gilbert syndrome in whom bilirubin level of > 1.5 x ULN will be allowed)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times ULN
- Hemoglobin >= 8 g/dL with or without transfusion in the last 7 days
- Absolute neutrophil count (ANC) >= 1000 without granulocyte colony stimulating factor (GCSF) or granulocyte-macrophage colony-stimulating factor (GMCSF) in the last 2 weeks prior to screening
- Platelets >= 50,000micro/mL
- For allo-HCT, no >= grade 2 visceral (gut or liver) acute graft versus host disease (GVHD) and no >= grade 3 or any other acute GVHD (patients with chronic GVHD will be allowed at the discretion of the investigator)
- Patient agrees to use acceptable contraceptive methods for the duration of time in the study, and to continue to use acceptable contraceptive methods for 2 months after the last tagraxofusp infusion
- Woman of child bearing potential (WOCBP) with a negative serum or urine pregnancy test within 14 days of tagraxofusp treatment
- Patient or patient's legal representative, parent(s) or guardian able to sign informed consent
- The patient can adhere to the study visit schedule and other protocol requirements, including follow-up for survival assessment
Exclusion Criteria:
- The patient has persistent clinically significant non-hematologic toxicities >= grade 2 (excluding alopecia, nausea, and fatigue)
- Evidence of central nervous system (CNS) involvement
- Uncontrolled and active pulmonary disease
- Requirement for oxygen treatment
- Receiving chemotherapy, radiotherapy or other anti-cancer therapy within 14 days of first dose of study drug. There must be at least a 6-week interval from the last immunotherapy therapy
- Uncontrolled infection
- Human immunodeficiency virus (HIV)/hepatitis B and/or C
- Any history of invasive malignancy in the last 2 years excluding any malignancy such as cervical cancer or skin cancer (excluding melanoma) that is considered cured at the time of screening
- Pregnant or breast-feeding woman
- Patient has uncontrolled intercurrent illness or medical/psychiatric condition that would limit compliance with study requirements or that would in the investigator's opinion place the patient at an unacceptably high risk for toxicities
- Clinical significant cardiopulmonary disease including uncontrolled or New York Heart Association (NYHA) class 3 or 4 congestive heart failure, uncontrolled angina, uncontrolled hypertension, uncontrolled arrhythmia, myocardial infarction or stroke within 6 months of first protocol treatment or corrected QT (QTc) > 480 ms
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (tagraxofusp-erzs)
Within day 45 and 180 after stem cell transplant, patients receive tagraxofusp-erzs IV over 15 minutes on days 1-3 of cycles 1-4 and days 1-2 of subsequent cycles.
Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
|
Given IV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tolerability of tagraxofusp post-stem cell transplantation (SCT)
Time Frame: Up to 1 year
|
Tolerability is defined as receipt of at least 75% of planned tagraxofusp doses in at least 4 cycles of therapy.
The percentage of patients considered 'tolerating' will be presented along with the associated 95% exact confidence interval.
|
Up to 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression free survival (PFS)
Time Frame: From treatment start date to date of disease progression or death, assessed up to 1 year
|
Will be estimated using the Kaplan-Meier method.
Median PFS as well as rates with corresponding 95% confidence intervals will be presented.
|
From treatment start date to date of disease progression or death, assessed up to 1 year
|
Overall survival (OS)
Time Frame: From treatment start date to death, assessed up to 1 year
|
Will be estimated using the Kaplan-Meier method.
Median OS as well as rates with corresponding 95% confidence intervals will be presented.
|
From treatment start date to death, assessed up to 1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Qaiser Bashir, MS, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018-0646 (Other Identifier: M D Anderson Cancer Center)
- NCI-2019-03832 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Blastic Plasmacytoid Dendritic Cell Neoplasm
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingBlastic Plasmacytoid Dendritic Cell NeoplasmUnited States
-
Dana-Farber Cancer InstituteAbbVieActive, not recruitingBlastic Plasmacytoid Dendritic Cell NeoplasmUnited States
-
Samsung Medical CenterCompletedBlastic Plasmacytoid Dendritic Cell NeoplasmKorea, Republic of
-
Immune Oncology Research InstituteRecruitingBlastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)United States, Armenia, Canada, Egypt, Georgia, United Kingdom, Cyprus, Italy, Turkey, India, Iraq, Taiwan, Kuwait
-
Centre Hospitalier Universitaire de BesanconCentre Hospitalier Universitaire Dijon; Centre Henri Becquerel; Maisonneuve-Rosemont... and other collaboratorsActive, not recruitingBlastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)France
-
Mustang BioTerminatedBlastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)United States
-
Cellectis S.A.TerminatedBlastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)United States
-
Centre Hospitalier Universitaire de BesanconCompletedBlastic Plasmacytoid Dendritic Cell Neoplasm | Hematological Malignancies
-
AvenCell Europe GmbHPHARMALOG Institut für klinische Forschung GmbHRecruitingBlastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Acute Myeloid Leukemia (AML)Germany
-
ImmunoGen, Inc.Active, not recruitingBlastic Plasmacytoid Dendritic Cell Neoplasm | Myeloproliferative NeoplasmUnited States, Spain, Germany, Italy, France, United Kingdom
Clinical Trials on Tagraxofusp-erzs
-
Stemline Therapeutics, Inc.CompletedMyelofibrosis | Chronic Myelomonocytic LeukemiaUnited States, Canada
-
Stemline Therapeutics, Inc.TerminatedAcute Myeloid LeukemiaUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...StemlineTherapeutics, Inc.RecruitingAcute Myeloid LeukemiaUnited States
-
M.D. Anderson Cancer CenterRecruitingChronic Myelomonocytic Leukemia | Myelodysplastic/Myeloproliferative Neoplasm | Chronic Myelomonocytic Leukemia-1 | Chronic Myelomonocytic Leukemia-2United States
-
Jonsson Comprehensive Cancer CenterStemline Therapeutics, Inc.WithdrawnAcute Myeloid LeukemiaUnited States
-
Gruppo Italiano Malattie EMatologiche dell'AdultoRecruitingAcute Myeloid LeukemiaItaly
-
Karen Ballen, MDRecruitingAcute Myeloid Leukemia | Myelofibrosis | Chronic Myelomonocytic LeukemiaUnited States
-
Joshua ZeidnerUniversity of North Carolina, Chapel Hill; Stemline Therapeutics, Inc.Not yet recruiting
-
Stemline Therapeutics, Inc.TerminatedMultiple MyelomaUnited States
-
Therapeutic Advances in Childhood Leukemia ConsortiumRecruitingLymphoma, B-Cell | Hodgkin Lymphoma | Lymphoblastic Lymphoma | Lymphoma, T-Cell | AML | Hematologic Malignancy | MDS | Acute Undifferentiated Leukemia | ALL | Mixed Phenotype Acute Leukemia | BPDCNUnited States, Australia